An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Results from the STOP-VT Study were presented at the ESC Congress 2011 today. This is the first ever multi-center, global, prospective trial to evaluate a Remote Magnetic Navigation system for the treatment of ischemic Ventricular Tachycardia.
The AF AWARE campaign today, at the European Society of Cardiology (ESC) Congress 2011 in Paris, announces the launch of the Atrial Fibrillation in Primary Care (AFIP) tool, developed to help primary care physicians (PCPs) with early diagnosis and optimal management of patients with atrial fibrillation.
New data show that, worldwide, one in three patients with atrial fibrillation (AF) who are at high risk for stroke are not being prescribed anticoagulant therapy, particularly vitamin K antagonists (VKA) – medicines known to significantly lower stroke risk in these patients.
Bristol-Myers Squibb Company and Pfizer Inc. today announced the main results of the Phase 3 clinical trial ARISTOTLE, which evaluated ELIQUIS compared to warfarin for the prevention of stroke or systemic embolism in 18,201 patients with atrial fibrillation and at least one risk factor for stroke.
W. L. Gore & Associates today reported that it has received zero accounts of erosion of the aortic root or the free wall of the atrium associated with the worldwide use of the GORE® HELEX® Septal Occluder.
These physicians are not anti-medicine. They are not trying to save money on their copayments or deductibles. And they are not trying to rein in the nation's soaring health-care costs, which at $2.7 trillion account for fully one sixth of every dollar spent in the U.S. They are applying to their personal lives a message they have become increasingly vocal about in their roles as biomedical researchers and doctors: more health care often means worse health.
By employing optogenetics, a new field that uses genetically altered cells to respond to light, and a tandem unit cell (TCU) strategy, researchers at Stony Brook University have demonstrated a way to control cell excitation and contraction in cardiac muscle cells, the details of which are published in the early online edition of Circulation: Arrhythmia & Electrophysiology: "Stimulating Cardiac Muscle by Light: Cardiac Optogenetics by Cell Delivery."
A new drug for gout could help very sick gout patients who don't get better with usual treatment, according to a new study. The research was designed and funded by the pharmaceutical company Savient, which markets the drug, called Krystexxa (pegloticase).
The latest research has revealed that a new drug for treating people with an irregular heartbeat has fewer side effects than the standard treatment and is just as good at cutting the risk of stroke. Rivaroxaban, which is easier for people to take, is as effective as warfarin at preventing blood clots and thus lowering the risk of stroke for patients with atrial fibrillation say researchers.
The Guidelines Department of the European Society of Cardiology has issued the following statement today: "The European Society of Cardiology (ESC) is aware of the early termination of the PALLAS trial because of adverse outcomes associated with dronedarone.
The compound, ursodeoxycholic acid (UDCA), is already used to lower cholesterol and help dissolve gallstones, and it's a key ingredient in many traditional Chinese medicines, which use bear bile. According to the latest research from Imperial College London it might also be able to treat abnormal heart rhythm, or arrhythmia, in fetuses and heart attack victims.
A synthesised compound which is also found in bear bile could help prevent disturbances in the heart's normal rhythm, according to research published today in the journal Hepatology by a team from Imperial College London.
Artificial nanoparticles are becoming increasingly pervasive in modern life. However, their influence on our health and the mechanisms by which they affect the human body remain largely shrouded in mystery.
The Mount Sinai Medical Center has become the first hospital on the east coast to perform a cardiac ablation procedure using the Thermocool Smarttouch Contact Force-Sensing Catheter for the treatment of symptomatic, paroxysmal atrial fibrillation (AF), or periodic rapid and irregular heartbeats.
A high-amplitude, and often painful, electrical shock is the only currently available method for treating certain cases of chronic cardiac arrhythmia. But now a new technique using much weaker impulses has been developed by an international team of physicists and cardiologists, including Alain Pumir, CNRS researcher at the ENS Lyon physics laboratory.
Merck, known as MSD outside the United States and Canada, and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc. today announced that they have entered into an agreement under which Merck, through a subsidiary, will acquire the exclusive rights to develop and commercialize the investigational intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico and the United States from Astellas.
A surgical team from the Montefiore Einstein Center for Heart and Vascular Care recently received certification training for implanting the SynCardia Total Artificial Heart, a replacement heart implanted in patients at risk of imminent death from heart failure.
Galectin Therapeutics Inc. today announced that it has entered into a research collaboration with Dr. Jose Jalife of the University of Michigan Medical School to better understand the relationship of Galectin-3 to cardiac fibrosis in chronic cardiac arrhythmias.
Global Health Partner: SECOND QUARTER 2011. Revenues increased by 14 percent to SEK 180.4 million.
An international team of scientists from the Max-Planck-Institute for Dynamics and Self-Organization, Cornell University the Ecole Normale Supérieure de Lyon, the University Medicine Göttingen, the Rochester Institute of Technology, and the Institut Non-Linéaire de Nice have developed a new low-energy method for terminating life-threatening cardiac fibrillation of the heart.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.